4DMT's one-shot gene therapy cuts anti-VEGF injections in severe wet AMD patients
4DMT Molecular Therapeutics Inc. is looking ahead to phase III as positive data continue to roll out for gene therapy candidate 4D-150 in wet age-related macular degeneration (AMD), with the results from the phase II portion of the phase I/II Prism trial showing the single-shot treatment significantly reduced the need for chronic anti-VEGF injections.
Dmt Molecular Therapeutics Inc 4d Molecular Therapeutics Inc 4d 150 Wet Age Related Macular Degeneration Wet Amd Gene Therapy
Source: bioworld.com